<DOC>
	<DOCNO>NCT00142428</DOCNO>
	<brief_summary>The main purpose study begin collect information try learn whether cetuximab work treat patient unresectable metastatic hepatocellular carcinoma .</brief_summary>
	<brief_title>Cetuximab Patients With Unresectable Metastatic Hepatocellular Carcinoma</brief_title>
	<detailed_description>The first step study examine tumor biopsy ( previously collect ) determine whether epidermal growth factor receptor ( EGFR ) positive EGFR negative . Both EGFR positive EGFR negative patient participate study time know whether negative positive receptor make difference study drug work tumor . By know tumor EGFR positive negative , able see difference way tumor respond cetuximab . Patients receive cetuximab intravenously weekly 6 week . Each 6-week period one cycle treatment . The first dose cetuximab large follow dos . For first clinic visit patient 's blood pressure , temperature , breathe heart rate take , , end , one-hour cetuximab administer . For visit , blood pressure , temperature , breathe heart rate take cetuximab administer . Before administration cetuximab , diphenhydramine also administer decrease chance allergic hypersensitivity reaction . The following test procedure perform week 1 , 3 5 6-week cycle treatment well end study treatment : physical exam , vital sign , medical history blood work . At end 6-week cycle CT and/or MRI perform measure tumor size . Long-term follow-up include physical exam bloodwork every 6 month . Patients remain cetuximab long disease progression intolerable side effect .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Unresectable metastatic hepatocellular carcinoma Measurable tumor Adequate hepatic function : total bilirubin &lt; 3.0mg/dl ; AST &lt; 7 x upper limit normal ( ULN ) . Adequate renal function : serum creatinine &lt; 2.0mg/dl Adequate bone marrow function : absolute neutrophil count ( ANC ) &gt; 1,000/mm3 ; platelet &gt; 75,000/mm3 . 02 prior systemic chemotherapy regimens hepatocellular carcinoma 18 year age old ECOG performance status 02 Life expectancy &gt; 12 week Surgery , exclude prior diagnostic biopsy venous access device placement , within 28 day study entry Uncontrolled serious medical psychiatric illness Irradiation chemotherapy disease within 28 day study entry Clinically apparent central nervous system metastases carcinomatous meningitis Received investigational agent within 30 day Cancer Liver Italian Program ( CLIP ) score &gt; 3 Acute hepatitis Active uncontrolled infection Significant history cardiac disease Prior cetuximab therapy specifically directly target EGFR pathway Prior allergic reaction chimerized murine monoclonal antibody therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>cetuximab</keyword>
	<keyword>Unresectable hepatocellular carcinoma</keyword>
	<keyword>Metastatic hepatocellular carcinoma</keyword>
</DOC>